Zucara Therapeutics Inc., a spin-off company by The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life.
